echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Wanchun Pharmaceutical's new drug Pranabrin submitted a marketing application to the FDA and NMPA

    Wanchun Pharmaceutical's new drug Pranabrin submitted a marketing application to the FDA and NMPA

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 31, Wanchun Pharmaceutical announced to submit to the US Food and Drug Administration and the China Medical Products Administration the first Chinese and US new drug listing application for the original innovative drug prinabulin.


    Pranabrin has a unique mechanism of action on dendritic cell (DC cell) maturation, antigen presentation and T cell activation.


    It is worth mentioning that in the second half of 2020, the National Food and Drug Administration (NMPA) of China and the US FDA respectively granted pranablin the "breakthrough treatment variety" and "breakthrough therapy designation" for the treatment of CIN.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.